Literature DB >> 15905173

Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase.

Marina K Holz1, John Blenis.   

Abstract

Here we demonstrate that mammalian target of rapamycin (mTOR) is phosphorylated in a rapamycin-sensitive manner. We show that S6 kinase 1 (S6K1), but not Akt, directly phosphorylates mTOR in cell-free in vitro system and in cells. Expression of a constitutively active, rapamycin- and wortmannin-resistant S6K1 leads to constitutive phosphorylation of mTOR, whereas knock-down of S6K1 using small inhibitory RNA greatly reduces mTOR phosphorylation despite elevated Akt activity. Importantly, phosphorylation of mTOR by S6K1 occurs at threonine 2446/serine 2448. This region has been shown previously to be part of a regulatory repressor domain. These sites are also constitutively phosphorylated in the breast cancer cell line MCF7 carrying an amplification of the S6K1 gene, but not in a less tumorigenic cell line, MCF10a. Many models for Akt signaling to mTOR have been presented, suggesting direct phosphorylation by Akt. These models must be reconsidered in light of the present findings.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15905173     DOI: 10.1074/jbc.M504045200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  152 in total

1.  2-Hydroxyestradiol slows progression of experimental polycystic kidney disease.

Authors:  Sharon Anderson; Terry T Oyama; Jessie N Lindsley; William E Schutzer; Douglas R Beard; Vincent H Gattone; Radko Komers
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-07

2.  mTOR-mediated activation of p70 S6K induces differentiation of pluripotent human embryonic stem cells.

Authors:  Charles A Easley; Ahmi Ben-Yehudah; Carrie J Redinger; Stacie L Oliver; Sandra T Varum; Vonya M Eisinger; Diane L Carlisle; Peter J Donovan; Gerald P Schatten
Journal:  Cell Reprogram       Date:  2010-06       Impact factor: 1.987

3.  Essential role of D1R in the regulation of mTOR complex1 signaling induced by cocaine.

Authors:  Laurie P Sutton; Marc G Caron
Journal:  Neuropharmacology       Date:  2015-08-24       Impact factor: 5.250

4.  Proximity ligation assay for high-content profiling of cell signaling pathways on a microfluidic chip.

Authors:  Matthias Blazek; Charles Betz; Michael Nip Hall; Michael Reth; Roland Zengerle; Matthias Meier
Journal:  Mol Cell Proteomics       Date:  2013-09-26       Impact factor: 5.911

5.  Ser2481-autophosphorylated mTOR colocalizes with chromosomal passenger proteins during mammalian cell cytokinesis.

Authors:  Alejandro Vazquez-Martin; Tamara Sauri-Nadal; Octavio J Menendez; Cristina Oliveras-Ferraros; Sílvia Cufí; Bruna Corominas-Faja; Eugeni López-Bonet; Javier A Menendez
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

Review 6.  AKT/PKB Signaling: Navigating the Network.

Authors:  Brendan D Manning; Alex Toker
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

7.  Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer.

Authors:  Akihiko Yoshizawa; Junya Fukuoka; Shigeki Shimizu; Konstantin Shilo; Teri J Franks; Stephen M Hewitt; Takeshi Fujii; Carlos Cordon-Cardo; Jin Jen; William D Travis
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

8.  Nerve growth factor inhibits Na+/H+ exchange and formula absorption through parallel phosphatidylinositol 3-kinase-mTOR and ERK pathways in thick ascending limb.

Authors:  David W Good; Thampi George; Bruns A Watts
Journal:  J Biol Chem       Date:  2008-07-25       Impact factor: 5.157

Review 9.  mTOR signaling: at the crossroads of plasticity, memory and disease.

Authors:  Charles A Hoeffer; Eric Klann
Journal:  Trends Neurosci       Date:  2009-12-04       Impact factor: 13.837

10.  Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.

Authors:  Ben A Hall; Tae Yeon Kim; Maxwell N Skor; Suzanne D Conzen
Journal:  Breast Cancer Res Treat       Date:  2012-07-29       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.